ArticleCancer communications (London, England)2019

The ACTIVE study protocol: apatinib or placebo plus gefitinib as first-line treatment for patients with EGFR-mutant advanced non-small cell lung cancer (CTONG1706).

Zhonghan Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.